EGFR and non-small cell lung carcinoma: Erlotinib was administered to 6.3% of all NSCLC patients, 33.6% of patients with EGFR-mutant tumors, 5.9% of patients with EGFR-wild type tumors and 4.8% of patients with unknown EGFR-mutant status (Table 2).